Efficacy and safety of Upadacitinib in moderate to severe CD

 

  • Title: Efficacy and safety of Upadacitinib  in moderate to severe CD
  • Study drug: Upadacitinib (Rinvoq)
  • Sponsor: AbbVie
  • Participating centers and contact: Insel Bern, PD Dr. med. Pascal Juillerat (Pascal.Juillerat@insel.ch)
  • Target population: Moderate to severe CD
  • Primary outcome:
  • Inclusion criteria: 
  • Exclusion criteria:
  • More information:
Back
Subscribe to our Newsletter

Sign up with your e-mail to receive IBDnet news and updates. We respect your privacy.